- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05760742
Evaluation of the Effects of a Novel Dietary Microalgae Based Ingredient on Muscle Recovery and Endurance Capacity (PORPHY-ONE)
September 21, 2023 updated by: Microphyt
Evaluation of the Protective Effects of a Novel Dietary Microalgae Supplement (PeLiv) Following Exercise-induced Muscle Damage and Influence on Endurance Capacity After Prolonged Consumption
The purpose of this investigation is to examine the effects of consuming a new dietary microalgae based supplement vs. placebo on neuromuscular function, energy utilization, soreness, perceptual wellness, swelling, and markers of muscle damage and inflammation in healthy young men before and after an acute exercise-induced muscle damage protocol (downhill running), and influence on endurance capacity after prolonged consumption.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32816
- University of Central Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male participants
- Healthy as assessed by Medical and activity history questionnaire (MHQ)
- Recreationally active according to American College of Sports Medicine guidelines
- Able to provide written and dated informed consent to participate in the study
Exclusion Criteria:
- Untrained
- Any response of "yes" on the PAR-Q+
- Physical limitations preventing running, countermovement jump, and strength (peak isometric torque and peak isokinetic torque) assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo group
2 capsules of Maltodextrin per day
|
2 months of supplementation with a placebo (Maltodextrin)
|
|
Experimental: MicAlgae100
2 capsules per day containing 100mg of microalgae based ingredient
|
2 months of supplementation with an innovative microalgae based ingredient
|
|
Experimental: MicAlgae250
2 capsules per day containing 250mg of microalgae based ingredient
|
2 months of supplementation with an innovative microalgae based ingredient
|
|
Experimental: MicAlgae500
2 capsules per day containing 500mg of microalgae based ingredient
|
2 months of supplementation with an innovative microalgae based ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neuromuscular function
Time Frame: From 0 to week 4
|
isokinetic peak torque in Newton per meter (N/m)
|
From 0 to week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Energy utilization (Oxygen consumption - VO2)
Time Frame: From 0 to week 4
|
Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis
|
From 0 to week 4
|
|
Energy utilization (Oxygen consumption - VO2)
Time Frame: From 0 to week 8
|
Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis
|
From 0 to week 8
|
|
Isokinetic neuromuscular function
Time Frame: From 0 to week 8
|
peak torque in Newton per meter (N/m)
|
From 0 to week 8
|
|
Isometric neuromuscular function
Time Frame: From 0 to week 8
|
peak torque in Newton per meter (N/m)
|
From 0 to week 8
|
|
Endurance capacity
Time Frame: From 0 to week 4
|
Maximal oxygen consumption (VO2max) determined during graded exercise test
|
From 0 to week 4
|
|
Endurance capacity
Time Frame: From 0 to week 8
|
Maximal oxygen consumption (VO2max) determined during graded exercise test
|
From 0 to week 8
|
|
Soreness and perceptual wellness
Time Frame: From 0 to week 4
|
Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol
|
From 0 to week 4
|
|
Soreness and perceptual wellness
Time Frame: From 0 to week 8
|
Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol
|
From 0 to week 8
|
|
Swelling - Muscle thickness (mm or cm)
Time Frame: From 0 to week 4
|
Evaluated using musculoskeletal ultrasound
|
From 0 to week 4
|
|
Swelling - overall thigh circumference (mm or cm)
Time Frame: From 0 to week 4
|
Evaluated using musculoskeletal ultrasound
|
From 0 to week 4
|
|
Creatine kinase (UI/I)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis
|
After 4 weeks of supplementation
|
|
lactate dehydrogenase (U/L)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis
|
After 4 weeks of supplementation
|
|
Myoglobin (ug/l)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis
|
After 4 weeks of supplementation
|
|
Interleukin-6 (pg/ml)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis - inflammation
|
After 4 weeks of supplementation
|
|
Tumor necrosis factor-α (ug/ml)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis - inflammation
|
After 4 weeks of supplementation
|
|
C-reactive protein (mg/l)
Time Frame: After 4 weeks of supplementation
|
Blood marker analyzis - inflammation
|
After 4 weeks of supplementation
|
|
Isometric Neuromuscular function
Time Frame: From 0 to week 4
|
Peak torque in Newton per meter (N/m)
|
From 0 to week 4
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: David Fukuda, PhD, University of Central Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 10, 2023
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
August 18, 2023
Study Registration Dates
First Submitted
February 23, 2023
First Submitted That Met QC Criteria
March 6, 2023
First Posted (Actual)
March 8, 2023
Study Record Updates
Last Update Posted (Actual)
September 22, 2023
Last Update Submitted That Met QC Criteria
September 21, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00004940
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.